Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910165 · ClinicalTrials.gov registry record · Phase 3
Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
A Phase 3 study, sponsored by St. Luke's Hospital, Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT04910165: Completed Phase 3 study, sponsored by St. Luke's Hospital, Pennsylvania.
NCT04910165 is a Phase 3 study that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04910165, a Phase 3 study, has completed, sponsored by St. Luke's Hospital, Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.
Primary Outcome
Inpatient post-operative stay after undergoing TKA procedure
Interventions
- DRUG Exparel
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 3 |
What the finished NCT04910165 record still lists
NCT04910165 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT04910165 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04910165 about?
NCT04910165 is a clinical study titled "Exparel Use in Adductor Canal Block After Total Knee Arthroplasty". Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operativ...
What is the current status of trial NCT04910165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2020-06-01. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT04910165?
The interventions under investigation include: Exparel (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT04910165?
This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04910165's enrollment target sits among peer trials
100 1681st of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI